01 Shift From 2d Monolayer Cell Cultures To 3d Spheroid-based Disease Models Research and drug discovery workflows are steadily transitioning from traditional two-dimensional cell cultures toward three-dimensional spheroid systems that replicate cell-to-cell interactions, oxygen gradients, and nutrient diffusion patterns observed in native tissues. Two-dimensional models often fail to capture tumor heterogeneity and microenvironment-driven responses, whereas spheroids provide physiologically relevant architectures suitable for oncology, toxicity screening, and target validation. This shift reflects growing emphasis on translational relevance and reduction of late-stage drug attrition.
02 Shift From Low-throughput Spheroid Generation To Scalable and Automation-compatible Platforms Spheroid production is evolving from labor-intensive, low-throughput techniques toward standardized platforms compatible with automation and high content screening. Advanced microplates, hanging drop systems, and microfabricated scaffolds enable uniform spheroid size and reproducibility across large assay volumes. This transition supports integration of spheroids into pharmaceutical screening pipelines where scalability, assay consistency, and data comparability drive adoption.
June 2026 Corning Incorporated expanded its 3D cell culture portfolio by launching advanced spheroid culture solutions designed to improve drug discovery, cancer research, and regenerative medicine applications.
April 2026 Thermo Fisher Scientific introduced upgraded spheroid culture systems featuring enhanced reproducibility and scalability for high-throughput drug screening and cell biology research.
January 2026 Merck KGaA expanded its life science portfolio with new spheroid culture media and extracellular matrix solutions supporting advanced 3D cell culture applications.
October 2025 InSphero expanded its 3D cell-based assay platform by introducing enhanced spheroid models for toxicity testing, oncology research, and pharmaceutical development.